Here's A Strategy To Play Amarin’s Upcoming Binary Event

Amarin’s (NASDAQ:AMRN) sell-off following the largely anticipated FDA approval of Vascepa has given investors a chance to buy the stock at an attractive valuation. However, another upcoming binary event is likely to shake up the stock before focus shifts to the long-term potential of the triglyceride-lowering drug.